Fluocinolone acetonide
Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching.
Fluocinolone acetonideCorticosteroidFluocinolone/hydroquinone/tretinoinAcetonideATC code C05ATC code S02ATC code D07Topical steroidList of MeSH codes (D04)ATC code S01PregnadieneList of drugs: FlCream (pharmaceutical)
United Kingdom Grants ILUVIEN(R) Marketing Authorization for the Treatment of ... - MarketWatch (press release)
Posted by admin / Under Fluocinolone Acetonide
 Proactive Investors Australia | United Kingdom Grants ILUVIEN(R) Marketing Authorization for the Treatment of ... MarketWatch (press release) ILUVIEN is Alimera's sustained release intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. The clinical trial data showed that in patients with chronic DME at ... PSivida Says UK Grants ILUVIEN Marketing Authorization For Treating Chronic DME pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization ... |
Published on Monday 21st of May 2012 10:46:06 PM
Alimera Sciences Reports First Quarter 2012 Financial Results - MarketWatch (press release)
Posted by admin / Under Fluocinolone Acetonide
Alimera Sciences Reports First Quarter 2012 Financial Results MarketWatch (press release) ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat chronic DME. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained ... |
Published on Monday 21st of May 2012 10:46:06 PM
DME implant receives Austrian - ModernMedicine
Posted by admin / Under Fluocinolone Acetonide
DME implant receives Austrian ModernMedicine Atlanta—The Austrian Agency for Health and Food Safety has granted marketing authorization to an intravitreal implant with sustained-release fluocinolone acetonide (Iluvien, Alimera Sciences Inc.) for the treatment of vision impairment associated with ... |
Published on Monday 21st of May 2012 10:46:06 PM
DME implant receives Austrian marketing OK - ModernMedicine
Posted by admin / Under Fluocinolone Acetonide
DME implant receives Austrian marketing OK ModernMedicine Atlanta—The Austrian Agency for Health and Food Safety has granted marketing authorization to an intravitreal implant with sustained-release fluocinolone acetonide (Iluvien, Alimera Sciences Inc.) for the treatment of vision impairment associated with ... |
Published on Monday 21st of May 2012 10:46:06 PM
Alimera's Iluvien gets its first EU green light in Austria - Pharma Times
Posted by admin / Under Fluocinolone Acetonide
Alimera's Iluvien gets its first EU green light in Austria Pharma Times Shares in the group rocketed nearly 30% on the Nasdaq yesterday (Tuesday) after the Austrian Agency for Health and Food Safety granted Iluvien (fluocinolone acetonide) marketing authorisation to treat vision impairment associated with chronic diabetic ... Alimera Eye Drug Inches Closer to Launch With Austria Approval pSivida ILUVIEN gains marketing authorization in Austria |
Published on Monday 21st of May 2012 10:46:06 PM
pSivida gets UK nod for behind-the-eye treatment - FierceDrugDelivery
Posted by admin / Under Fluocinolone Acetonide
pSivida gets UK nod for behind-the-eye treatment FierceDrugDelivery Iluvien uses the platform to deposit sub-microgram amounts of fluocinolone acetonide into the eye to treat chronic diabetic macular edema. The UK authorization follows one from Austria last month, and the news highlights the treatment's market ... |
Published on Monday 21st of May 2012 10:46:06 PM
UK approves sight loss drug for diabetics - Pharma Times
Posted by admin / Under Fluocinolone Acetonide
UK approves sight loss drug for diabetics Pharma Times Iluvien is an intravitreal implant - inserted in the back of the patient's eye - that delivers tiny levels of the active substance fluocinolone acetonide for up to three years. Its approval was based on clinical trial data showing that in patients with ... |
Published on Monday 21st of May 2012 10:46:06 PM
Alimera Sciences to Release First Quarter Fiscal Year 2012 Financial Results - MarketWatch (press release)
Posted by admin / Under Fluocinolone Acetonide
Alimera Sciences to Release First Quarter Fiscal Year 2012 Financial Results MarketWatch (press release) Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. |
Published on Monday 21st of May 2012 10:46:06 PM
Foamix Obtains US Patent "Waterless Hydrophilic Foam" for Dermatological and ... - Healthcare Global (press release)
Posted by admin / Under Fluocinolone Acetonide
Foamix Obtains US Patent "Waterless Hydrophilic Foam" for Dermatological and ... Healthcare Global (press release) This formulation platform is specifically important for drugs that degrade in the presence of water, and it enabled Foamix to formulate several water-sensitive drugs, including various corticosteroids (eg, Fluocinolone Acetonide, Betamethasone Valerate ... |
Published on Monday 21st of May 2012 10:46:06 PM
Alimera Sciences CEO Daniel Myers Took 63% Pay Cut in 2011 - cbl - Citybizlist (press release)
Posted by admin / Under Fluocinolone Acetonide
Alimera Sciences CEO Daniel Myers Took 63% Pay Cut in 2011 - cbl Citybizlist (press release) ... develops prescription ophthalmic pharmaceuticals, focusing presently on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide, a non-proprietary corticosteroid. |
Published on Monday 21st of May 2012 10:46:06 PM
Find news
Share this!